Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Achieve Life SciencesACHV +13.58%32 EV-to-OCF is -15.00 as of Aug. 19, 2026. GuruFocus rates ACHV with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Achieve Life Sciences ranks better than 74.36% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Achieve Life Sciences's Enterprise Value is $705.41 Mil.
Achieve Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-47.02 Mil. Therefore, Achieve Life Sciences's EV-to-OCF for today is -15.00.
The historical rank and industry rank for Achieve Life Sciences's EV-to-OCF or its related term are showing as below:
ACHV'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.1 Med: -0.45 Max: 0.69
Current: -15
During the past 13 years, the highest EV-to-OCF of Achieve Life Sciences was 0.69. The lowest was -15.10. And the median was -0.45.
ACHV's EV-to-OCF is ranked better than 74.36% of 1408
companies
in the Biotechnology industry
Industry Median: -3.66
vs ACHV: -15.00
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Achieve Life Sciences (NAS:ACHV) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Achieve Life Sciences's PE Ratio (TTM) for today is calculated as:
Achieve Life Sciences's share price for today is $8.538.
Achieve Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Achieve Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achieve Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's EV-to-OCF falls into.
Achieve Life Sciences's current Enterprise Value is $705.41 Mil.
Achieve Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achieve Life Sciences (ACHV) has a EV-to-OCF of -15.00 as of Aug. 19, 2026. According to the industry distribution chart, Achieve Life Sciences ranks #361 out of 1408 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Achieve Life Sciences' EV-to-OCF too high?
Achieve Life Sciences' current EV-to-OCF is -15.00. Based on the distribution chart, Achieve Life Sciences ranks #361 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' EV-to-OCF compare to MDXG and RGNX?
According to the Biotechnology industry distribution chart, Achieve Life Sciences ranks #361 out of 1408 companies for EV-to-OCF. This puts Achieve Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Achieve Life Sciences's current EV-to-OCF is -15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (ACHV) has a current EV-to-OCF of -15.00. The current EV-to-OCF is -15.00. Achieve Life Sciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Achieve Life Sciences (ACHV), the current EV-to-OCF is -15.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score
Get the complete analysis for ACHV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACHV has been successfully added to your 
